Johnson & Johnson (NYSE:JNJ) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On July 3, Janssen-Cilag, a company of Johnson & Johnson, reported applying to the European Medicines Agency to expand the use of AKEEGA, a drug that combines niraparib and abiraterone acetate.
The new application seeks approval for treating adults with metastatic hormone-sensitive prostate cancer who have specific genetic changes called homologous recombination repair gene alterations. While treatments for mHSPC have improved, over 20% of mHSPC patients have HRR gene alterations, including the BRCA1/2 genes. These patients often have worse outcomes and limited treatment options.
A smiling baby with an array of baby care products in the foreground.
Janssen-Cilag’s submission is based on results from the Phase 3 AMPLITUDE study. This study tested niraparib and abiraterone acetate with prednisone or prednisolone versus the current standard treatment. The combination significantly delayed cancer progression and the worsening of symptoms.
Johnson & Johnson is an international healthcare company that develops and sells medical products. The company operates through two main segments, which include Innovative Medicine and MedTech.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
